Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 05/31/23
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 03/22/23
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public OfferingGlobeNewsWire • 02/03/23
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 02/01/23
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 10/10/22
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial HypertensionBusiness Wire • 05/23/22
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq RulesBusiness Wire • 05/18/22
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business UpdateBusiness Wire • 03/31/22
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific SessionsBusiness Wire • 03/30/22
Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)GlobeNewsWire • 01/12/22
Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical ProgramsGlobeNewsWire • 01/04/22
Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business UpdateBusiness Wire • 11/16/21
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)Business Wire • 10/06/21
Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/09/21
Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business UpdateBusiness Wire • 08/17/21
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)Business Wire • 08/12/21